Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 50,000 Class A shares on 07/10/2024, with an aggregate market value of $374,000. These shares were originally acquired on 09/01/2016 as founders shares and were part of Gibson's compensation from the issuer. This planned sale follows a recent history of transactions where a total of 200,000 shares were sold over the past three months, generating gross proceeds of $1,681,000.

Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 50,000 Class A shares on 07/10/2024, with an aggregate market value of $374,000. These shares were originally acquired on 09/01/2016 as founders shares and were part of Gibson's compensation from the issuer. This planned sale follows a recent history of transactions where a total of 200,000 shares were sold over the past three months, generating gross proceeds of $1,681,000.